LifeMD Misses Q4 Revenue Estimates with $46.9M, Beats on Adjusted EBITDA
Summary
LifeMD, Inc. reported fourth-quarter revenue of $46.9 million, falling short of the IBES estimate of $48.6 million. Despite the revenue miss, the company surpassed adjusted EBITDA expectations, posting $4.8 million compared to an estimated $4.06 million. This mixed earnings report presents a nuanced picture for investors, with top-line performance lagging but profitability exceeding forecasts. The company also issued a full-year revenue outlook of $220-230 million, which is generally in line with analyst consensus. Traders will likely focus on how the market reconciles the revenue shortfall with the stronger-than-expected profitability and forward guidance.
At the time of this announcement, LFMD was trading at $3.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $150.2M. The 52-week trading range was $2.56 to $15.84. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.